Patrick et al. from Yale University designed and synthesized SyAM-P mimetic antibody analogs, which were able to simultaneously bind to the PSMA antigen on the surface of prostate cancer cells and FcγRI on the surface of immune cells, effectively guiding immune cells to target prostate cancer cells (Figure 4C). Here, FOLH1 is linked to prostate carcinoma.